SynthesisFrontiers in oncology2026
Immunoconjugates in cervical cancer: a bibliometric and thematic mapping analysis of global research trends, 2015-2024.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoconjugates, particularly antibody drug conjugates, are emerging as clinically relevant options for recurrent or metastatic cervical cancer. A quantitative overview of how this field has evolved over the last decade remains limited. Methods: Publications from 2015-2024 were retrieved from the Web of Science Core Collection and Scopus, restricted to English articles and reviews, de-duplicated, and screened by two reviewers, yielding 244 records for analysis. Bibliometric indicators were calculated using bibliometrix in R, while VOSviewer and CiteSpace were used for keyword co-occurrence mapping and burst detection, respectively. Results: Output increased markedly after 2021, consistent with a shift toward clinical translation. Keyword mapping identified five interlinked themes spanning clinical safety and toxicity management, hematologic malignancy related translational influences, preclinical mechanisms, gynecologic oncology applications, and clinical trial design with emerging therapeutics. Burst analysis indicated a temporal transition from early model based and mechanistic terms to clinically oriented hotspots, including tissue factor and immunotherapy associated concepts. Conclusions: The literature depicts rapid maturation of immunoconjugate research in cervical cancer from foundational studies toward clinically actionable targets, safety optimization, and combination strategies, providing a roadmap for prioritizing future translational efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.